NE HSV2 is a vaccine candidate for the prevention of herpes simplex virus-2 (HSV-2).
BlueWillow’s nanoemulsion (NE) adjuvant is uniquely suited to enable vaccines for sexually transmitted infections, wherein pathogens enter the body across mucosal surfaces.
When used with intranasal vaccination, the NE adjuvant elicits both mucosal and systemic immunity. The mucosal immunity elicited by NE vaccines provides critical protection against these infections at their port of entry.
Recent research conducted by the University of Cincinnati in conjunction with BlueWillow has demonstrated that an intranasal NE vaccine elicits protection in both the prophylactic & therapeutic guinea pig models for HSV-2.
This represents the first vaccine to show efficacy in both models.
BlueWillow’s intranasal nanoemulsion (NE) vaccine is uniquely suited to offer protection against this painful and distressing affliction, through its ability to elicit both a systemic and mucosal immune response.
BlueWillow's NanoVax™ technology platform utilizes a novel oil-in-water emulsion adjuvant to enable intranasal vaccines that elicit mucosal and systemic Th1/Th17 immunity.
BlueWillow’s vaccines uniquely elicit mucosal antibodies that serve as “bouncers at the door” as the body’s first line of defense to keep infections out.